5-Year Outcomes with Cobimetinib plus Vemurafenib in $\less$i$\greater$BRAF$\less$/i$\greater$V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Studyстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или Scopus
Авторы:
Ascierto Paolo A.,
Dréno Brigitte,
Larkin James,
Ribas Antoni,
Liszkay Gabriella,
Maio Michele,
Mandalà Mario,
Demidov Lev,
Stroyakovskiy Daniil,
Thomas Luc,
de la Cruz-Merino Luis,
Atkinson Victoria,
Dutriaux Caroline,
Garbe Claus,
Hsu Jessie,
Jones Surai,
Li Haocheng,
McKenna Edward,
Voulgari Athina,
McArthur Grant A.
Аннотация:The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAFV600 mutation-positive advanced melanoma. We report long-term follow-up of coBRIM, with at least 5 years since the last patient was randomized.